Abstract:Targeted therapy is a promising treatment for cancer patients. Antitumor antibody drug conjugates(ADC), the new generation of antibody technology, combine the target-specificity of monoclonal antibody (mAb) and the highly active cell-killing of drugs, taking advantages of the best characteristics of both components. ADC contain three main components: antibody, linker and cytotoxics (also frequently referred as payload). Antibodies can recognize and specifically bind to the tumor-specific antigens, leading to an antibody-assisted internalization, and payload release under low pH or the action of lysosomal proteases, so as to achieve the specificity killing of cancer cells without damaging normal tissue cells. This paper reviews the emergence and development of ADC, and discusses several possible key influential factors in the development process of ADC.

Development of antibody-drug conjugates as targeted cancer therapeutics